MARKET

SCNX

SCNX

Scienture Holdings, Inc
NASDAQ
2.278
-0.157
-6.45%
After Hours: 2.190 -0.088 -3.86% 19:30 11/20 EST
OPEN
2.355
PREV CLOSE
2.435
HIGH
2.370
LOW
2.000
VOLUME
29.86K
TURNOVER
--
52 WEEK HIGH
18.75
52 WEEK LOW
2.000
MARKET CAP
4.07M
P/E (TTM)
-0.0490
1D
5D
1M
3M
1Y
5Y
1D
Scienture’s Arbli and Rezenopy Growth Supports Positive Outlook; $6 Price Target Reaffirmed
TipRanks · 2d ago
Scienture Holdings, Inc. GAAP EPS of -$3.76, revenue of $1.25M
Seeking Alpha · 5d ago
Scienture Holdings Q3 EPS $(3.76) Misses $(1.57) Estimate, Sales $1.255M Beat $1.220M Estimate
Benzinga · 5d ago
Weekly Report: what happened at SCNX last week (1109-1113)?
Weekly Report · 5d ago
When Will Scienture Holdings, Inc. (NASDAQ:SCNX) Become Profitable?
Simply Wall St · 11/11 10:33
Weekly Report: what happened at SCNX last week (1102-1106)?
Weekly Report · 11/09 09:31
Scienture Holdings Reports Annual Meeting Stockholder Voting Results
TipRanks · 11/03 21:47
Weekly Report: what happened at SCNX last week (1026-1030)?
Weekly Report · 11/02 09:31
More
About SCNX
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Webull offers Scienture Holdings Inc stock information, including NASDAQ: SCNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCNX stock methods without spending real money on the virtual paper trading platform.